BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

November 18, 2013 8:00 AM UTC

Algeta ASA (OSE:ALGETA) was off NOK4.60 to NOK263.40 on Friday after the European Commission approved an MAA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases.

The pharma plans to launch the product in the EU next month. Xofigo is approved for the indication in the U.S...